The evaluation of dupilumab treatment response in atopic dermatitis patients.
Atopic dermatitis
dupilumab
scoring atopic dermatitis
Journal
Northern clinics of Istanbul
ISSN: 2536-4553
Titre abrégé: North Clin Istanb
Pays: Turkey
ID NLM: 101684520
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
05
2020
accepted:
08
11
2020
entrez:
14
4
2021
pubmed:
15
4
2021
medline:
15
4
2021
Statut:
epublish
Résumé
This study aims to demonstrate real-life effectiveness of dupilumab treatment in moderate-to-severe atopic dermatitis patients. The 14 patients diagnosed with moderate-to-severe atopic dermatitis were included in this study. All of the patients started dupilumab treatment in our faculty between October 2019 and October 2020. The patients were evaluated at the beginning of the treatment and after 12 weeks of treatments. The baseline scoring atopic dermatitis (SCORAD) scores, the total immunoglobulin E (IgE) levels, and the visual analog scale (VAS) of 0-10 points for itch intensity compared with the post-treatment scores. The SCORAD scores, the serum total IgE levels, and the VAS itch scores of the patients receiving dupilumab treatment dropped significantly following 12 weeks of dupilumab treatment. No significant correlation was demonstrated between the initial SCORAD scores and the serum total IgE values. Besides, no correlation was shown to exist in the reduction of the SCORAD and the serum total IgE values after dupilumab treatment. Dupilumab treatment showed significant improvement in disease severity with remarkable reduction in serum total IgE levels.
Identifiants
pubmed: 33851078
doi: 10.14744/nci.2020.42375
pii: NCI-8-145
pmc: PMC8039099
doi:
Types de publication
Journal Article
Langues
eng
Pagination
145-149Informations de copyright
Copyright: © 2021 by Istanbul Northern Anatolian Association of Public Hospitals.
Déclaration de conflit d'intérêts
Conflict of Interest: No conflict of interest was declared by the authors.
Références
J Am Acad Dermatol. 2017 Aug;77(2):274-279.e3
pubmed: 28606711
Br J Dermatol. 2015 Jun;172(6):1621-1627
pubmed: 25683671
J Eur Acad Dermatol Venereol. 2019 Aug;33(8):1562-1568
pubmed: 30959559
Br J Dermatol. 2019 Nov;181(5):1072-1074
pubmed: 31021399
Ann Med Interne (Paris). 1985;136(5):419-22
pubmed: 4062142
Am J Clin Dermatol. 2018 Aug;19(4):617-624
pubmed: 30027349
N Engl J Med. 2014 Jul 10;371(2):130-9
pubmed: 25006719
N Engl J Med. 2016 Dec 15;375(24):2335-2348
pubmed: 27690741
Dermatology. 2017;233(5):344-357
pubmed: 29320765
J Allergy Clin Immunol. 2017 Dec;140(6):1708-1710.e1
pubmed: 28625808
J Dermatolog Treat. 2019 Oct 28;:1-7
pubmed: 31647347
Dermatology. 1993;186(1):23-31
pubmed: 8435513
J Am Acad Dermatol. 2019 Jul;81(1):143-151
pubmed: 30825533